Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Sep;37(3):211-6.
doi: 10.1007/s13318-011-0076-3. Epub 2011 Dec 13.

Different effects of dihydropyridine calcium channel antagonists on CYP3A4 enzyme of human liver microsomes

Affiliations

Different effects of dihydropyridine calcium channel antagonists on CYP3A4 enzyme of human liver microsomes

Zongling Xia et al. Eur J Drug Metab Pharmacokinet. 2012 Sep.

Abstract

The present study investigated inhibitory effects of 1,4-dihydropyridines (1,4-DHPs) calcium channel antagonists (1,4-DHP-CCAs) on cytochromeP450 3A4 (CYP3A4) of human liver microsomes and further explored importance of 1,4-DHPs molecular structural descriptors. Partial Least Squares method was applied to probe the quantitative relationships between the 1,4-DHPs molecular structural descriptors and its inhibitory actions, which demonstrated that different 1,4-DHP-CCAs could inhibit CYP3A4 enzyme's activity differently. The K (i) values of nicardipine, lercandipine, cilnidipine, nitrendipine, lacidipine, nifedipine, felodipine were 10.13, 10.17, 11.44, 23.90, 29.34, 29.06 and 32.64 μmol L⁻¹, respectively. It is suggested that the 1,4-DHPs molecular structural descriptors are the most important for its inhibitory effects based on the quantitative structure-activity relationship (QSAR) formula. The LogP was positively correlated to the K (i), whereas molecular weight and molecule volume were negatively correlated. It is concluded that analysis of K (i) of 1,4-DHPs derivatives on the CYP3A4 activity may apply for the QSAR formula at the initial stage of clinical application of new drugs.

PubMed Disclaimer

References

    1. Biochem Pharmacol. 2007 Jun 30;74(1):1-9 - PubMed
    1. Biol Pharm Bull. 2005 May;28(5):882-5 - PubMed
    1. S Afr Med J. 2001 Dec;91(12):1060-8 - PubMed
    1. Chem Biol Interact. 2004 Apr 15;147(3):319-29 - PubMed
    1. Prog Cardiovasc Dis. 2001 Nov-Dec;44(3):207-16 - PubMed

Publication types

MeSH terms

LinkOut - more resources